drugset / Trial / NCT03937869

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

NCT03937869

Phase 4 Completed 40 enrolled Lupin Research Inc
NaSingle-groupOpen-labelTreatment

Summary

A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV

Timeline

Start
2018-11-28
Primary completion
2020-11-05
Completion
2020-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Secnidazole Small molecule 2 g Oral

Indications